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Neuroblastoma is the most common extra-cranial tumour in chil-
dren. Its clinical behaviour ranges from spontaneous regression or
complete remission after minimal drug therapy to unfavourable
outcome from aggressive tumour growth despite intensive multi-
modal therapy (Katzenstein and Cohn, 1998). The benign differen-
tiated counterpart, ganglioneuroma, usually has an excellent
prognosis. Both tumours originate from the sympathetic nervous
system and like all tumours of neuroendocrine origin they are able
to produce different neuropeptides (Langley, 1994).
Measurement or identification of these neuropeptides has
become increasingly important in screening, diagnosis and follow-
up of several tumours or tumour syndromes (Pollak and Schally,
1998; Lee and Evans, 1997). Intervention by peptide analogues is
a well established treatment in several modalities of neuro-
endocrine tumours and can relieve symptoms (Öberg, 1998).
Neuropeptide Y (NPY), a 36-residue peptide present throughout
the peripheral and central nervous systems, is synthesized as a
preprohormone, preproNPY (97 residues), first cleaved to proNPY
(69 residues), and eventually to the biologically active, C-termi-
nally amidated peptide, NPY, (1–36) (Lundberg et al, 1982;
Adrian et al, 1983a; Allen, 1990). Both proNPY and NPY as well
as other, not structurally identified, molecular forms of NPY-like
immunoreactivity have been identified in neuroblastoma and
pheochromocytoma tumours (Adrian et al, 1983b; O’Hare and
Schwartz, 1989b; Kogner et al, 1993; deS Senanayake et al, 1995).
Plasma concentrations, but not tumour concentrations, of NPY
have been shown to be of value to monitor follow-up of treatment
in neuroblastoma, and high concentrations have been associated
with poor outcome (Kogner, 1995; Dötsch et al, 1998). Five
different receptor subtypes for NPY have been cloned with
different affinity profiles for NPY, truncated forms of NPY, and
NPY-related peptides and several different physiological effects
has been attributed to NPY through these receptors (Michel et al,
1998). NPY has also been implicated in cellular events, e.g. to be
mitogenic in vascular smooth muscle cells and in neuroblastoma
cells in vitro (Zukowska-Grojec et al, 1993; Shorter and Pence,
1997) and to be angiogenic both in vitro and in vivo, an effect
mediated through the Y2-receptor (Zukowska-Grojec et al, 1998).
The aim of the present study was to investigate the processing of
proNPY and its correlation to different clinical parameters. Analysis
of proNPY processing was carried out using gel-permeation chro-
matography and an antiserum specific for the mid-portion of NPY.
Peptides with NPY-like immunoreactivity (NPY-LI) were isolated,
chromatographically purified and characterized by amino acid
sequence analysis and mass spectrometry.
MATERIAL AND METHODS
Patient material and sample handling
Samples from primary tumours from 18 children with neuro-
blastoma and one child with ganglioneuroma containing significant
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selected from a series of tumours (Kogner, 1995). The tumours
were diagnosed according to international criteria and neuro-
blastomas of all clinical stages were included (Brodeur et al,
1993). One metastasis, one healthy adrenal gland from a child with
neuroblastoma, one ganglioneuroma and five phaeochromocytoma
tumours from adult patients were also investigated. Tumour tissue,
obtained at surgery, was frozen on solid CO2 and kept at –70°C
until extraction. Six of the children with neuroblastoma died
within 4–38 months from diagnosis, whereas the remaining chil-
dren have been followed for 48–118 months without any evidence
of disease. The study was approved by the ethics committee of
Karolinska Institutet, Stockholm, Sweden.
Analytical peptide extraction
Extraction was performed by homogenization and boiling the
tumour samples for 10 min in 10 volumes (minimum 2 ml) acetic
acid (1 mol l–1). After centrifugation at 2000 g for 15 min, the
supernatants were lyophilized and dissolved in RIA-buffert.
Preparative peptide extraction
Preparative extraction was performed on two samples from chil-
dren with neuroblastoma. After homogenization, boiling, centrifu-
gation and decantation, trifluoroacetic acid (TFA) was added to the
supernatant to a final concentration of 0.1% and the material was
loaded onto SepPak cartridges (Waters, Milford, MA, USA),
primed with 10 ml 80% methanol, 0.1% TFA, and equilibrated
with 10 ml water, 0.1% TFA. After loading the sample, the
cartridge was flushed with 2 ml water, 0.1% TFA and immunore-
active material was eluted with 4 ml 80% methanol, 0.1% TFA.
The eluates were dried under vacuum at 40°C, and dissolved in
formic acid (1 mol l–1), 0.02% sodium aside, before application
onto gel-permeation chromatography.
Gel-filtration and reversed-phase high-pressure liquid
chromatography (RP-HPLC)
A Sephadex G-50 superfine column (2.6 ´ 95 cm) (Amersham
Pharmacia Biotech, Sweden) was eluted with formic acid
(1 mol l–1), 0.02% sodium azide, 0.1% bovine serum albumin
(BSA) (BSA was excluded in preparative runs) at a flow rate of
0.5 ml min–1. The column was calibrated using synthetic NPY
(1–36) and 3H-NPY (1–36) (Peninsula, Belmont, CA, USA). Void
volume (V0) was determined with Blue dextran and total volume
(Vt) with 22Na. Fractions (2 ml in analytical and 8 ml in prepara-
tive runs) were collected and lyophilized for subsequent analysis
for NPY-LI. For structural analysis, fractions were lyophilized and
dissolved in 0.1% TFA, pooled and further purified by RP-HPLC.
RP-HPLC was carried out by C18 (4.6 ´ 250 mm) and C4 
wide-pore (1 ´ 150 mm) columns (Vydac, Hesperia, CA, USA)
using a conventional system and a SMART-system (Amersham
Pharmacia Biotech), respectively. The columns were eluted
(1 ml min–1, and 30 ml min–1, respectively) at room temperature
with linear gradients of acetonitrile in water with 0.1% TFA or
0.1% TFA, 0.1% heptasulfonic acid. The eluate was monitored
with UV-detection at 214 and 280 nm.
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Table 1 Results from measurements of NPY-LI and clinical data for individual patients.
Age at Follow- ProNPY- MYCN
Pat. Diagnosis diagnosis Gender up Status NPY-LI ProNPY NPY proc. ampl.
(months) (months) (pmol g–1) (fmol) (fmol) (%) (+/–)
T61 AD 41 F 88 NED 9.6 1487 806 35.1 –
T41 GN 31 F 94 NED 2133 614 9570 93.8 –
T63 MET 41 F 88 NED 545 2370 1979 45.5 –
T90 NB 1 13 M 61 NED 128 2162 4769 68.8 –
T107 NB 1 18 F 60 NED 682 2159 9755 81.9 –
T29 NB 2 0 F 118 NED 262 0 3392 100.0 –
T92 NB 2 12 M 62 NED 92 79 6204 98.7 –
T116 NB 2 33 F 52 NED 31.2 317 2692 89.5 –
T65 NB 2 103 F 73 NED 195 0 423 100.0 –
T26 NB 3 3 F 81 NED 451 2046 7904 79.4 –
T64 NB 3 6 M 80 NED 119 1248 676 35.1 –
T93 NB 3 21 M 6 DOD 203 1798 1644 47.8 +
T38 NB 4 8 F 4 DOD 282 2171 300 12.1 +
T88 NB 4 11 F 4 DOD 143 1437 483 25.2 +
T50 NB 4 24 M 10 DOD 226 6135 3149 33.9 –
T52 NB 4 32 M 18 DOD 116 634 6919 91.6 –
T62 NB 4 41 F 88 NED 78 0 328 100.0 –
T51 NB 4 60 M 48 NED 177 0 1289 100.0 –
T01 NB 4 60 F 38 DOD 220 1330 300 18.4 –
T66 NB 4S 0 M 80 NED 50 580 3861 86.9 –
T95 NB 4S 2 F 58 NED 55 32 901 96.6 –
8302 PHEO 1003 0 900 100.0
8305 PHEO 259 0 1116 100.0
P7 PHEO F 305 293 3356 92.0
P8 PHEO F 3955 0 2122 100.0
P9 PHEO M 281 172 2842 94.3
Healthy adrenal (AD), phaeochromocytomas (PHEO), ganglioneuromas (GN), neuroblastomas (NB) of different clinical stages (1–4 and 45) and metastasis
(MET). No evidence of disease (NED), dead of disease (DOD)Structural analysis
The primary structure of peptides was investigated by N-terminal
amino acid sequence analysis using an Applied Biosystems 476
instrument (Perkin-Elmer, Norwalk, CT, USA) and phenyltiohy-
dantion detection with a 120 analyser. Molecular mass were deter-
mined by MALDI-TOF mass spectrometry (Finnigan, San Jose,
CA, USA). Both methods were carried out according to the manu-
facturers’ instructions.
Fractions containing NPY immunoreactivity with a larger
Stokes radius were lyophilized after gel-permeation chromatog-
raphy and reconstituted in Veronal buffer, pH 8.6. Endoproteinase
Lys-C (Sigma, St. Louis, MO, USA), 16 ng in 10 ml, was added
prior to incubation at 37°C for 60 min.
Radioimmunoassay (RIA)
NPY-LI was analysed with RIA performed under non-equilibrium
conditions using intact porcine NPY (1–36) as standard. The anti-
serum was raised in rabbit and had specificity for the mid-portion
of NPY (Theodorsson-Norheim et al, 1985). The cross-reactivity
for human NPY (1–36) and (3–36) was 65.2 and 19.2%,
respectively.
MYCN oncogene amplification by Southern blot
analysis
MYCN oncogene copy number was determined by Southern blot
analysis performed as previously described (Hedborg et al, 1992)
using the MYCN clone pNB 19–21. MYCN amplification was
scored when the gene copy number was three or more in each
haploid genome (Seeger et al, 1985).
Calculation of processing ratio and statistics
The extent of proNPY-processing was calculated by dividing the
amount of NPY-LI eluting at the position of NPY (1–36) with the
amount of all NPY-LI. Significance was calculated according to
Fischer’s exact test, Mann–Whitney U test, Spearman and Pearson
correlation coefficients. Survival probability was calculated
according to Kaplan–Meier and compared using the logrank test.
RESULTS
Gel-permeation chromatography identified two molecular forms
of NPY-LI with different Stokes radii (Figure 1). Some of the
neuroblastomas, the ganglioneuroma and the pheochromocytomas
contained only little or nothing of the larger form of NPY-LI (first
peak), (Table 1). Incubation with Endoproteinase Lys-C of the
material with NPY-LI from the first peak (representing a larger
Stokes radius) and subsequent gel-permeation chromatography,
showed cleavage of the high molecular precursor to a component
detected at a position slightly earlier than intact NPY (1–36) (data
not shown). Incubation with 6 mol l–1 urea for eliminating the
possibility of protein binding or dimerization did not affect the
result of gel-permeation chromatography (data not shown). The
second peak, with a smaller Stokes radius, was present in all
samples and eluted at the position of intact NPY (1–36)/3H-NPY
(1–36).
Tumour tissue from two children with neuroblastoma was
further extracted on a preparative basis and gel-permeation
chromatography was carried out. The second peak material with a
smaller Stokes radius was further purified by RP-HPLC in several
steps before amino acid sequence analysis. The result showed an
amino acid sequence identical with that of human NPY (1–36)
which was followed for 21 and 36 cycles, respectively. In the latter
tumour, the amino-acid sequence analysis also revealed an N-
terminally truncated form of NPY, NPY (3–36). This was
confirmed by mass spectrometry, showing the molecular masses
for the oxidized, C-terminally amidated forms of NPY (1–36)
and NPY (3–36) (Figure 2).
The processing ratio in the healthy adrenal was 35% (Figure 3),
(Table 1). In the ganglioneuroma and the adult pheochromocy-
tomas it was more than 90% (98%, 92–100%, median, range),
whereas the ratio in the neuroblastomas varied (80%, 12–100%).
Metastatic tissue, available from one child, showed a processing
ratio of 46%, as compared to 100% in the corresponding primary
tumour. A significantly lower degree of proNPY processing was
seen in neuroblastomas at advanced stage (stages 3 and 4) (41%,
12–100%) as compared to stages 1, 2 and 4S (93%, 69–100%, P =
0.012) (Figure 3). A processing of less than 50% was significantly
correlated with poor prognosis (P = 0.004) and with a significant
difference in survival probability (P < 0.001, c2 = 12.63) as
analysed according to Kaplan–Meier (Figure 4). MYCN
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Figure 1 Gel-permeation chromatography of NPY-LI in tumour tissue from
a 3-month-old girl with neuroblastoma stage 3 (A) and an 8-month-old girl
with MYCN amplified neuroblastoma stage 4 (B). The degree of proNPY
processing was 74 and 12%. The girl with neuroblastoma stage 3 was alive
and without evidence of disease after 81 months of follow-up, whereas the
girl with neuroblastoma stage 4 died of disease after 8 months. The eluting
position of intact NPY and total volume (Vt) is indicated. Void volume was at
fraction number 75 (not shown).amplification was also significantly correlated to prognosis
(P = 0.025) and to a low degree of proNPY processing (P = 0.025)
but not to tumour stage (P = 0.147) and there was a significant
difference in survival probability as analysed according to
Kaplan–Meier (P < 0.001, c2 = 21.19) (Figure 3). No other corre-
lation was identified for the data in Table 1, e.g. there was no
correlation between the concentration of NPY-LI and the
processing degree using either Pearson (r2 = 0.05, P > 0.2) or
Spearman (P > 0.7) coefficients of variation.
DISCUSSION
Pheochromocytomas and neuroblastomas may produce large
amounts of NPY and the concentration of NPY in plasma can be a
valuable marker in the diagnosis and monitoring of these diseases
(Adrian et al, 1983b; Kogner et al, 1993; deS Senanayake et al,
1995). In the present material, a decreased intracellular processing
of proNPY was significantly correlated with both widespread
disease and poor outcome. Furthermore, a truncated form of NPY
was identified indicating that the processing of proNPY and NPY
in neuroblastoma may increase the possibility to modulate the
interaction with different NPY receptors.
In this series of 25 tumours and one control adrenal, two major
molecular forms of NPY-LI were identified (Figure 1). The larger
molecular form of NPY-LI was deduced to be proNPY as was
indicated by Endoproteinase Lys-C (Jekel et al, 1983).
Endoproteinase Lys-C cleaves the peptide bond C-terminally of
the Lys-residue, and can thereby be expected to cleave the 69
amino acid precursor proNPY C-terminally of the only lysine-
residue present (position 38) in proNPY, generating the two frag-
ments NPY (1–36)-Gly-Lys and Arg-CPON (C-flanking Peptide
Of NPY) (O’Hare and Schwartz, 1989a).
The molecular form of NPY-LI with a smaller Stokes radius
eluted at the same position as intact NPY. By subsequent purifica-
tion and amino acid sequence analysis, intact NPY was identified
in one tumour whereas the other tumour was shown to contain
both intact NPY and an N-terminally truncated form of NPY, NPY
(3–36), also confirmed with mass spectrometry (Figure 2).
The processing degree of proNPY to NPY in neuroblastoma
was significantly higher in the more differentiated tumours as a
processing of less than 50% was seen only in the most
unfavourable tumours (stage 3 and 4) with regional or metastatic
spread (P = 0.012) (Figure 3). A processing of less than 50%
was also significantly correlated with a poor survival probability
as five of the six children in this group died within 38 months from
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Figure 4 Survival probability analysed according to Kaplan–Meier
correlated to the degree of proNPY processing in 18 children with
neuroblastoma. Survival probability for children with proNPY processing of
more than 50% was 91.7 ± 8.0% (n = 12) and for children with a processing
of less than 50% it was 16.7 ± 15.2% (n = 6) (P < 0.001, c2 = 12.63).diagnosis (P = 0.004) (Figure 4). In the group of children with a
processing of 50% or more, 11 out of 12 children were alive
without evidence of disease during a follow-up time of 48 to 118
months.
Variation in the degree of processing is in agreement with an in
vitro study using eight different neuroblastoma cell lines where the
processing degree varied between 33 and 72% (O’Hare and
Schwartz, 1989a). However, they are in contrast to another study
by the same group where three neuroblastoma tumours all had
more than 90% processing (O’Hare and Schwartz, 1989b). The
difference in these results may be due to the fact that cell lines are
most often raised from more malignant tumours, whereas the clin-
ical tumours in the study may be of more benign stages (not speci-
fied in the articles).
Prohormone processing has been investigated in a number of
endocrine tumours but has so far not been implicated to be of prog-
nostic value (Rehfeld et al, 1996). The significant differences,
although analysed in a limited number of samples, may indicate
that biochemical events involved in the formation of NPY may be
a part of an aggressive phenotype and that proNPY processing
may be an indicator of prognosis in children with neuroblastoma.
The conversion of proNPY to the active peptide, NPY (1–36)
occurs intracellulary within secretory vesicles involving several
different enzymes. Among these enzymes the prohormone conver-
tases (PC) 1 (also called PC 3) and PC 2 seem to be both the most
substrate-specific and tissue-specific for proNPY processing
(Wulff et al, 1993; Hook et al, 1996; Paquet et al, 1996). The
present results may be derived from variation in PC-expression in
the tumours; further studies are needed to elucidate this issue.
A low degree of proNPY processing in the more aggressive
neuroblastomas may seem to contradict to the previous reported
correlation between elevated concentrations of NPY-LI in plasma
and poor outcome and relapse of disease (Kogner, 1995; Dötsch et
al, 1998). However, the degree of proNPY processing is not corre-
lated to the total amount of NPY-LI present (Table 1).
Furthermore, no correlation between NPY mRNA expression and
NPY-LI plasma concentration (tumour release) has been found
(Dötsch et al, 1998). Thus, translation, transcription and cellular
release are not necessarily linked.
The five pheochromocytomas from adult patients did not show
significant amounts of proNPY. This is in agreement with previous
studies of pheochromocytoma tumour extracts showing only one
immunoreactive form of NPY (Adrian et al, 1983b; Corder et al,
1984; Allen et al, 1987; O’Hare and Schwartz, 1989b). No classi-
fication of the pheochromocytomas has been indicated in these
previous studies, and also not in the present material. However, the
amounts detected in all samples indicate that the processing degree
in general, is high in pheochromocytoma tumour tissue.
Amplification of the MYCN oncogene is an established
predictor of poor prognosis in neuroblastoma and is strongly corre-
lated with clinically advanced stages (Seeger et al, 1985; Brodeur
et al, 1992). In the present study, all three tumours with MYCN
amplification showed a low degree of proNPY processing, were of
advanced clinical stage and the children died during follow-up
(Table 1 and Figure 3). However, a low degree of proNPY-
processing had a higher correlation to advanced tumour stage and
poor outcome than MYCN amplification.
By amino acid sequence analysis and mass spectrometry, intact
NPY was identified in one tumour investigated, whereas another
tumour was shown to contain both intact NPY and an N-terminally
truncated form of NPY, NPY (3–36) (Figure 2). Evidently, none of
the chromatographic methods, or the RIA, was able to separate
intact NPY from NPY (3–36). This lack of specificity is probably
a feature that is in common with most, if not all, other investiga-
tions.
NPY (3–36) has earlier been identified in a human somato-
statinoma of the pancreas but has, to our knowledge, not been
found in normal human tissue or blood (Shaw et al, 1993). NPY
has an N-terminally tyrosine followed by a prolyl residue. This
structure renders the peptide resistant to generalized aminopepti-
dase degradation but susceptible to more specialized enzymes
(Mentlein, 1988). Several enzymes have recently been investi-
gated and human dipeptidyl amino peptidase (DPP) IV was the
only enzyme with high activity for NPY generating Tyr-Pro dipep-
tides (Mentlein et al, 1993). DPP IV has been identified on the
surface of endothelial cells, T-lymphocytes (CD 26), hepatocytes
and in the intestinal and kidney brush border membranes, but
adrenal or tumour tissue has not been investigated (Mentlein et al,
1993).
The multitude of receptors and ligands indicate that the
processing of proNPY and intact NPY offers a potential to modu-
late the physiological and biological actions of NPY (Michel et al,
1998). Processing of NPY to NPY (3–36) generates a molecule,
which does not bind to the Y1 receptor (Grandt et al, 1996). The
presence of both intact NPY and NPY (3–36) in the same tumour
tissue has not been reported earlier. These findings indicate the
presence of DPP IV on the surface of cells in neuroblastoma
tumours, converting non-receptor selective intact NPY into Y2-,
Y3- and Y5 receptor-selective NPY (3–36), thereby creating a
potential for modulation, or even a shift, in biological actions. The
Y1 and Y2 receptor may be expressed in neuroblastoma cell lines.
(Wahlestedt et al, 1992). and formation of NPY (3–36) in neurob-
lastoma tumours may be of particular significance since the Y2
receptor mediates the angiogenic activity of the ligand NPY
(3–36) in vitro and in vivo (Zukowska-Grojec et al, 1998).
In conclusion, a low degree of proNPY processing in tumour
tissue was correlated to advanced disease with regional or
metastatic spread and poor outcome in neuroblastoma.
ProNPY/NPY processing within the same tumour tissue generated
NPY (3–36), a molecule known to have different receptor selec-
tivity in comparison with intact NPY. Simple methods are needed
to specifically measure the different forms of NPY-LI that are
present in neuroblastoma tumour tissue.
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